Startup profile for Garner Health: latest funding, latest known valuation, total disclosed funding, investors, status, sources, and why the company is interesting. Part of the Venture Capital Tracker startup directory.

Startup profile · funding coverage

Garner Health funding, valuation and investors

Employer benefit that ranks in-network doctors on outcomes and reimburses members who see top performers.

Keep track of Garner Health

Save this profile to your VCT watchlist for a quick return.

View watchlist

Funding, valuation & investors

Answer-first snapshot

Latest funding

Series E

$100M · May 2026

Latest known valuation

$2.74B

Series E · May 2026

Total disclosed equity funding

$218M

Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.

Current status

private

growth · New York, New York

Sources: latest funding Last verified: 2026-07-25

Overview

Garner Health is a New York–based employer health benefit that helps members find high-performing in-network doctors and reduces out-of-pocket costs when they use them. Founded in 2019 by CEO Nick Reber, the company analyzes one of the largest U.S. medical claims datasets — over 60 billion records covering 320 million patients — using 550+ specialty-specific quality metrics to identify top providers. Garner operates as a supplemental Health Reimbursement Arrangement layered on existing plans: employees use the Garner app or concierge to book Top Providers, then qualify for reimbursement on qualifying medical bills. The company reports serving nearly 800 employer clients, ~$200M gross ARR doubling YoY for five periods, and average employer healthcare spend reductions of 10%+ in year one.

Why Garner Health is interesting

Garner pairs 60B+ claims records with HRA-style reimbursements so employers can steer members to high-outcome doctors without changing networks — a rare healthtech model with ~800 clients and $2.74B valuation at Series E.

Product & use cases

Garner ranks individual physicians on outcomes and efficiency using merged commercial, Medicare, Medicaid, and price-transparency data, then surfaces Top Providers via app, API, or coordinator UI. Financial incentives — employer-funded HRAs — reward members who choose higher-quality care.

  • Employers reducing healthcare spend without changing insurance networks
  • Members finding in-network Top Providers by symptom, specialty, or ZIP
  • Benefits advisors offering nondisruptive care-navigation add-ons
  • Health plans and providers embedding Garner quality scores in referral workflows

Key facts

  • Series E (May 2026): $100M led by Index Ventures at $2.74B valuation — PR Newswire
  • Series D (Feb 2026): $118M led by Kleiner Perkins at $1.35B valuation
  • ~800 employer clients; claims dataset spans 60B+ records and 320M patients
  • Reports ~$200M gross ARR doubling YoY for five consecutive periods (HIT Consultant, May 2026)
  • CEO Nick Reber founded Garner after personal experience with misdiagnosed back pain and four surgeries

Funding history (newest first)

Investors in our directory

Funds linked from Garner Health's profile — open a fund page for stage focus and related deal articles.

Competitive landscape

Edge: Bottom-up physician scoring from 60B+ claims — not reviews or directory data — combined with reimbursement mechanics that actually shift member behavior.

Employer care navigation is crowded, but most vendors steer to networks or centers of excellence rather than individual physician quality at scale. Garner's moat is proprietary claims analytics plus HRA mechanics that tie savings to measurable outcomes — Index Ventures cited it as a leading applied-AI use case in healthcare.

  • Accolade direct

    Employer health navigation and advocacy; less emphasis on claims-based physician ranking at individual-doctor granularity.

  • Transcarent direct

    Employer care navigation and surgery steerage; broader navigation vs. Garner's data-driven provider scoring.

  • Healthgrades adjacent

    Consumer physician ratings; lacks Garner's claims depth and employer-funded incentive layer.

  • Castlight Health (Virta Health) incumbent

    Legacy employer transparency tools; Garner argues traditional directories miss outcome-based ranking.

Notable stories

  • Nick Reber started Garner after four back surgeries traced to misdiagnosis — he concluded healthcare fails because patients lack quality data and financial incentives, not because doctors don't care (MedCity News, May 2026).
  • Garner closed $118M Series D in February 2026 and $100M Series E just three months later — an unusually fast double-up reflecting employer demand for measurable cost outcomes.

Industries

Healthtech AI & Machine Learning Enterprise SaaS

Related funding articles

Venture Capital Tracker pieces that cover Garner Health's financing or category context.

FAQs about Garner Health

Practical answers founders, operators, and investors typically search for.

Garner is an employer health benefit that ranks in-network doctors on clinical outcomes using claims data and reimburses members who visit Top Providers via a supplemental HRA.
Garner closed a $100 million Series E led by Index Ventures (/fund/index-ventures) at a $2.74 billion valuation in May 2026.
Directory-backed investors include Index Ventures (/fund/index-ventures), Kleiner Perkins (/fund/kleiner-perkins), Redpoint (/fund/redpoint-ventures), Thrive Capital (/fund/thrive-capital), Sequoia (/fund/sequoia), and Founders Fund (/fund/founders-fund).
No. Garner is a separate employer-funded HRA benefit layered on existing health plans — it helps members find better doctors and covers qualifying out-of-pocket costs.
Garner analyzes 60B+ medical claims using 550+ specialty-specific quality and efficiency metrics — not patient reviews — to identify the top ~20% of in-network providers.
Both serve employers, but Garner focuses on claims-based individual physician scoring plus financial incentives; Accolade emphasizes broader health navigation and advocacy.
2019 in New York by CEO Nick Reber.
Profitability is not publicly disclosed; the company reports strong revenue growth (~130% YoY as of Series D) and ~$200M gross ARR.
Garner reported nearly 800 clients at its May 2026 Series E announcement.
Growth stage — Series E at $2.74B valuation as of May 2026.

By Venture Capital Tracker

Last updated:

Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.